Pre-Eclampsia Pipeline Report 2023: Emerging Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Companies by DelveInsight | Kyowa Kirin Co., Ltd, Pharming Group, Amag Pharmaceuticals, MirZyme, Evergreen Therapeutics, Dilafor

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Pre-Eclampsia pipeline constitutes 5+ key companies continuously working towards developing 5+ Pre-Eclampsia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

DelveInsight's 'Pre-Eclampsia Pipeline Insight 2023' report provides comprehensive global coverage of available, marketed, and pipeline Pre-Eclampsia therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Pre-Eclampsia pipeline domain.

For Pre-Eclampsia emerging drugs, the Pre-Eclampsia pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Request for sample page @ https://www.delveinsight.com/report-store/pre-eclampsia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Pre-Eclampsia Pipeline Report
• Pre-Eclampsia Companies across the globe are diligently working toward developing novel Pre-Eclampsia treatment therapies with a considerable amount of success over the years.
• Leading Pre-Eclampsia companies developing novel drug candidates to improve the Pre-Eclampsia treatment landscape include Kyowa Kirin Co., Ltd, Pharming Group, Amag Pharmaceuticals, MirZyme, Evergreen Therapeutics, Dilafor, and others.
• Promising Pre-Eclampsia pipeline therapies in various stages of development include KW3357, rhC1INH protein replacement therapy, siRNA therapy, C103, GMA312, Tafoxiparin, EG-101, and others.
Request a sample and discover the recent breakthroughs happening Pre-Eclampsia pipeline landscape in @ https://www.delveinsight.com/sample-request/pre-eclampsia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Pre-Eclampsia Overview
Pre-Eclampsia is a pregnancy complication marked by high blood pressure and signs of organ damage, most commonly the liver and kidneys. Pre-Eclampsia is a pregnancy condition characterized by hypertension (high blood pressure) and proteinuria (the presence of protein in your urine). It usually appears during the third trimester. The condition affects between 5% and 8% of pregnancies and has serious health consequences for mothers and babies. There is no single cause, but genetic factors and blood vessel problems are two possibilities. Pre-Eclampsia, if left untreated, can cause serious - even fatal - complications for both mother and baby.

Pre-Eclampsia Pipeline Analysis: Drug Profile
Tafoxiparin: Dilafor
Tafoxiparin, a proprietary heparan sulfate mimetic, has been shown in preclinical and clinical data to supplement and fulfill the role of heparan sulfate, which is required for optimal oxytocin effectiveness. Tafoxiparin's mechanism of action has been supported by preclinical experiments and clinical studies when used in conjunction with oxytocin in current clinical practice. Tafoxiparin can improve uterine contractions and may promote cervical softening, potentially lowering the incidence of protracted labor and its associated complications. The drug is currently in Phase III development for the treatment of preeclampsia.

KW3357: Kyowa Kirin Co., Ltd.
KW-3357 is an antithrombin (AT) drug developed using recombinant DNA and sugar-chain control technology. It is a recombinant AT preparation with the same amino acid sequence and sugar chain structure as human natural AT. AT inhibits blood coagulation by forming a complex with the proteolytic enzyme's coagulation factor. Since July 2015, KW-3357 has been approved in Japan for treating thrombophilia due to congenital AT deficiency (CAD) and disseminated intravascular coagulation (DIC) and is marketed under the brand name ACOALAN. Kyowan Kirin Co., Ltd is currently developing KW3357 in collaboration with Japan Blood Products Organization for Preeclampsia.

Pre-Eclampsia Pipeline Therapies and Key Companies
• KW3357: Kyowa Kirin Co., Ltd.
• rhC1INH protein replacement therapy: Pharming Group
• Tafoxiparin: Dilafor
• EG-101: Evergreen Therapeutics
• Preeclampsia Research Project: MirZyme
• siRNA therapy: Comanche Biopharma
• C 103: Vicore Pharma
• GMA 312: Gmax Biopharm

Learn more about the Pre-Eclampsia emerging pipeline therapies @ https://www.delveinsight.com/sample-request/pre-eclampsia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Pre-Eclampsia Pipeline Therapeutics Assessment
By Product Type
• Monotherapy
• Combination Therapy

By Stage
• Discovery
• Pre-Clinical
• Phase I
• Phase II
• Phase III
• Pre-registration

By Route of Administration
• Subcutaneous
• Intravenous
• Oral

By Molecule Type
• Replacement Therapy
• Physiological Saline
• Antihypertensive

DelveInsight's Pre-Eclampsia pipeline Report covers around 5+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Pre-Eclampsia Pipeline Analysis:
The Pre-Eclampsia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Pre-Eclampsia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pre-Eclampsia Treatment.
• Pre-Eclampsia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pre-Eclampsia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pre-Eclampsia market.

Download Sample PDF Report to know more about Pre-Eclampsia drugs and therapies@ https://www.delveinsight.com/sample-request/pre-eclampsia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Pre-Eclampsia Pipeline Report
• Coverage: Global
• Key Pre-Eclampsia Companies: Kyowa Kirin Co., Ltd, Pharming Group (AMS: PHARM), Amag Pharmaceuticals, MirZyme, Evergreen Therapeutics, Dilafor, and others.
• Key Pre-Eclampsia Pipeline Therapies: KW3357, rhC1INH protein replacement therapy, siRNA therapy, C103, GMA312, Tafoxiparin, EG-101, and others.

Dive deep into rich insights for Pre-Eclampsia emerging therapies and assessment; visit @ https://www.delveinsight.com/report-store/pre-eclampsia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1.Introduction
2.Pre-Eclampsia Executive Summary
3.Pre-Eclampsia Overview
4.Pre-Eclampsia Pipeline Therapeutics
5.Pre-Eclampsia Pipeline: Late Stage Products (Phase III)
6.Pre-Eclampsia Pipeline: Mid Stage Products (Phase II)
7.Pre-Eclampsia Pipeline: Early Stage Products (Phase I/II)
8.Pre-Eclampsia Pipeline: Preclinical Stage Products
9.Pre-Eclampsia Pipeline: Discovery Stage Products
10.Pre-Eclampsia Pipeline Therapeutic Assessment
11.Pre-Eclampsia Pipeline: Inactive Products
12.Collaborations Assessment- Licensing / Partnering / Funding
13.Unmet Needs
14.Market Drivers and Barriers
15.Appendix
16.About DelveInsight

For further information on the Pre-Eclampsia current pipeline therapeutics, reach out @ @ https://www.delveinsight.com/sample-request/pre-eclampsia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• Anaphylaxis Market: https://www.delveinsight.com/report-store/anaphylaxis-market
• Aortic Stenosis Market: https://www.delveinsight.com/report-store/aortic-stenosis-market
• Cluster Headaches Market: https://www.delveinsight.com/report-store/cluster-headache-market
• Familial Primary Pulmonary Hypertension Market: https://www.delveinsight.com/report-store/familial-primary-pulmonary-hypertension-market
• Hpv-induced Cancers Market: https://www.delveinsight.com/report-store/hpv-induced-cancers-market
• Meningioma Market: https://www.delveinsight.com/report-store/meningioma-market
• Optic Neuritis Market: https://www.delveinsight.com/report-store/optic-neuritis-market
• Partial Seizure Market: https://www.delveinsight.com/report-store/partial-seizure-market
• Progressive Multifocal Leukoencephalopathy Market: https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-market
• Rhino Conjunctivitis Market: https://www.delveinsight.com/report-store/rhino-conjunctivitis-market
• Thymic Carcinoma Market: https://www.delveinsight.com/report-store/thymic-carcinoma-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Chronic Lymphocytic Leukemia Market: https://www.delveinsight.com/report-store/relapsed-chronic-lymphocytic-leukemia-cll-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Aesthetic Implants Market: https://www.delveinsight.com/report-store/aesthetic-implants-market
• Multiple Myeloma Market: https://www.delveinsight.com/report-store/multiple-myeloma-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Lewy Body Dementia Market: https://www.delveinsight.com/report-store/lewy-body-dementia-market
• Alopecia Market: https://www.delveinsight.com/report-store/alopecia-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Pruritus Market: https://www.delveinsight.com/report-store/pruritus-market
• Eczema Market: https://www.delveinsight.com/report-store/eczema-market
• Concussions Market Size: https://www.delveinsight.com/report-store/concussions-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Actinic Keratosis Market: https://www.delveinsight.com/report-store/actinic-keratosis-market
• Alzheimer Disease Market: https://www.delveinsight.com/report-store/alzheimers-disease-ad-market
• Chemotherapy Induced Thrombocytopenia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-thrombocytopenia-market-size
• Foot And Ankle Devices Market: https://www.delveinsight.com/report-store/foot-and-ankle-devices-market
• Parkinson's Disease Market: https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment
• Ventilator Market: https://www.delveinsight.com/report-store/ventilators-market

Contact Us:
Ankit Nigam
info@delveinsight.com
+1(919)321-6187
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.